Search - tctmd.com

Displaying 1 - 13 of 13

Sort: Relevancy | Date

News Conference News TCT 2023

MitraClip G4 Data Impress, but Some Question the Reproducibility: EXPAND G4

Yael L. Maxwell

November 02, 2023

News Conference News TCT 2023

Durability, Hemodynamics Look Good for SAVR, TAVI in PARTNER 3

Michael O'Riordan

November 01, 2023

News Conference News TCT 2023

VIVA: No Difference Between TAVI and SAVR for Small Aortic Annuli

L.A. McKeown

October 27, 2023

Presentation TCT 2023

Position 3: Initial TAVR

Presenter: Mathew Williams

October 25, 2023

Presentation TCT 2023

Importance of Patient Reported Outcomes

Presenter: David Cohen

October 24, 2023

Presentation TCT 2023

An Echo Deep Dive of the PARTNER 5-Year Study

Presenter: Philippe Pibarot

October 24, 2023

News Conference News TCT 2023

Some Surprises in Low-Risk TAVI Follow-up: PARTNER 3 and Evolut Trials

Michael O'Riordan

October 24, 2023

Presentation TCT 2023

Important Secondary Endpoints From the PARTNER 3 5-YEAR STUDY

Presenter: Raj Makkar

October 24, 2023

Presentation TCT 2023

Perspectives on Mortality in the PARNTER 5-Year Study

Presenter: Vinod Thourani

October 24, 2023

Presentation TCT 2023

Five-year Echocardiographic Outcomes From The PARTNER 3 Low-risk Randomized Trial

Presenter: Rebecca Hahn

October 24, 2023

Presentation TCT 2023

Five-Year Clinical and Echocardiographic Outcomes From The PARTNER 3 Low-Risk Randomized Trial

Presenter: Martin Leon

October 24, 2023

Presentation TCT 2023

Call to Action: Recommendations for Strengthening the Partnership Between Patients and Clinicians

Presenter: Susan Strong

October 23, 2023

Video

» Topical Discussion

First Insights on the PARTNER 3 Trial 5-year Data

November 2, 2023

Advertisement

MitraClip G4 Data Impress, but Some Question the Reproducibility: EXPAND G4

Durability, Hemodynamics Look Good for SAVR, TAVI in PARTNER 3

VIVA: No Difference Between TAVI and SAVR for Small Aortic Annuli

Position 3: Initial TAVR

Importance of Patient Reported Outcomes

An Echo Deep Dive of the PARTNER 5-Year Study

Some Surprises in Low-Risk TAVI Follow-up: PARTNER 3 and Evolut Trials

Important Secondary Endpoints From the PARTNER 3 5-YEAR STUDY

Perspectives on Mortality in the PARNTER 5-Year Study

Five-year Echocardiographic Outcomes From The PARTNER 3 Low-risk Randomized Trial

Five-Year Clinical and Echocardiographic Outcomes From The PARTNER 3 Low-Risk Randomized Trial

Call to Action: Recommendations for Strengthening the Partnership Between Patients and Clinicians

First Insights on the PARTNER 3 Trial 5-year Data

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content